At a glance
Bremelanotide-related research on melanocortin signaling.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Studies address specific sexual-function outcomes and populations. A research-vial preparation should not be assumed equivalent to a regulated finished medicine.[2][1][4]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of PT-141.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 2 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–8 | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
| Weeks 13–16 | 1500 mcg (1.5 mg) | 45 units (0.45 mL) |
Route & Frequency: Inject once daily subcutaneously (abdomen or thigh). The subcutaneous route provides approximately 100% bioavailability and is better tolerated than intranasal delivery[2]. The FDA-approved on-demand regimen uses 1.75 mg SC before intercourse (max 8 doses/month)[2]; however, daily protocols at 2.5 mg have been studied in obese women for appetite and weight reduction[3], suggesting daily use can be tolerated. This schedule uses a conservative titration starting below the FDA on-demand dose.
Nasal Actuation Calculation Table (Placeholders)
| Concentration (mcg/mL) | Pump Output (mL/actuation) | Amount per Actuation (mcg) | Actuations per mL | Total Actuations in Reconstituted Volume |
|---|---|---|---|---|
| [A] | [B] | [A] × [B] | 1 / [B] | [Recon. vol. mL] × (1 / [B]) |
| [C] | [D] | [C] × [D] | 1 / [D] | [Recon. vol. mL] × (1 / [D]) |
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support sexual desire and arousal through central melanocortin receptor activation[2].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 500–1500 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 500 mcg daily for the first 8 weeks to assess tolerance.
- Escalate: Increase to 1000 mcg daily during Weeks 9–12.
- Target: 1500 mcg daily during Weeks 13–16 if well tolerated.
- Frequency: Once per day (subcutaneous).
- Timing: Any consistent time; rotate injection sites between abdomen and thighs.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[8].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[10].
- Clean the vial stopper and skin with alcohol; allow to dry[6].
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[6][7].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[6].
- Rotate sites systematically (abdomen, thighs) to avoid lipohypertrophy[5][10].
- Discard needles and syringes in a sharps container after one use[6].
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (PT-141, 10 mg each):
- 8 weeks (56 days × 500 mcg = 28 mg) ≈ 3 vials
- 12 weeks (56 × 500 + 28 × 1000 = 56 mg) ≈ 6 vials
- 16 weeks (56 × 500 + 28 × 1000 + 28 × 1500 = 98 mg) ≈ 10 vials
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
PMC (2022) — Bremelanotide for treatment of female hypoactive sexual desire: mechanism, trials, and safety review (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Source document
Mayo Clinic — Bremelanotide (subcutaneous route): side effects, dosage, and precautions (opens in a new tab)www.mayoclinic.org
Back to overview ↑ - 05
Public health resource
MedlinePlus — Patient instructions for subcutaneous injections: site rotation and technique (opens in a new tab)medlineplus.gov
Back to overview ↑ - 06
Public health resource
CDC — Vaccine administration: subcutaneous route (angle, site, and no-aspiration guidance) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 07
Public health resource
CDC — Vaccine administration best practices: during the injection (technique diagram) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
CDC — Storage and handling of immunobiologics: cold-chain and lyophilized product guidance (opens in a new tab)www.cdc.gov
Back to overview ↑ - 09
Research publication
PMC (2019) — Bremelanotide: first approval (comprehensive drug profile including cardiovascular considerations) (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 15
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.